Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome

Oruc C. U., Akpinar Y. E., Dervisoglu E., Amikishiyev S., Salmaslioglu A., Gurdol F., ...Daha Fazla

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, cilt.55, sa.1, ss.139-144, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1515/cclm-2016-0329
  • Dergi Adı: CLINICAL CHEMISTRY AND LABORATORY MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.139-144
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: In individuals with atherosclerotic risk factors, endothelial dysfunction (ED) appears as an early phase in the development of clinical symptoms. Recent studies indicate that adropin, a newly identified peptide, participates in cardiovascular health through the regulation of several metabolic events including angiogenesis and blood flow. In this study, we aimed to determine the relation of adropin with biochemical and radiologic parameters which reflect ED such as endothelial nitric oxide synthase (eNOS), endothelin 1 (ET-1), nitric oxide (NO) and flow-mediated dilatation (FMD) along with the routine biochemical measurements in patients recently diagnosed with metabolic syndrome (MetS).